Regulation of lymphatic vascular morphogenesis: Implications for pathological (tumor) lymphangiogenesis

Experimental Cell Research

Volumn 319, Issue 11, 2013, Pages 1618-1625

  Martinez Corral, Ines ^a   Makinen, Taija ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Lymphangiogenesis; Lymphatic vessel; Lymphedema; Metastasis

Indexed keywords

EPHRIN B2; I KAPPA B KINASE GAMMA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR NRP2; TRANSCRIPTION FACTOR PROX1; TRANSCRIPTION FACTOR SOX18; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

BASEMENT MEMBRANE; CANCER LOCALIZATION; CANCER PROGNOSIS; CARDIOVASCULAR SYSTEM; CELL DIFFERENTIATION; CELL FATE; CELL JUNCTION; CELL MIGRATION; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTERNALIZATION; LYMPH NODE METASTASIS; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM; LYMPHEDEMA; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

ANIMALIA;

LYMPHANGIOGENESIS; LYMPHATIC VESSEL; LYMPHEDEMA; METASTASIS;

ANIMALS; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MORPHOGENESIS; NEOPLASMS;

EID: 84879605182     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.01.016     Document Type: Review

References (72)

1. Alitalo K. The lymphatic vasculature in disease. Nat. Med. 2011, 17:1371-1380.
2. Baluk P., Fuxe J., Hashizume H., Romano T., Lashnits E., Butz S., Vestweber D., Corada M., Molendini C., Dejana E., McDonald D.M. Functionally specialized junctions between endothelial cells of lymphatic vessels. J. Exp. Med. 2007, 204:2349-2362.
3. Schulte-Merker S., Sabine A., Petrova T.V. Lymphatic vascular morphogenesis in development, physiology, and disease. J. Cell Biol. 2011, 193:607-618.
4. Wigle J.T., Harvey N., Detmar M., Lagutina I., Grosveld G., Gunn M.D., Jackson D.G., Oliver G. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J. 2002, 21:1505-1513.
5. Srinivasan R.S., Dillard M.E., Lagutin O.V., Lin F.J., Tsai S., Tsai M.J., Samokhvalov I.M., Oliver G. Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. Genes Dev. 2007, 21:2422-2432.
6. Yaniv K., Isogai S., Castranova D., Dye L., Hitomi J., Weinstein B.M. Live imaging of lymphatic development in the zebrafish. Nat. Med. 2006, 12:711-716.
7. Okuda K.S., Astin J.W., Misa J.P., Flores M.V., Crosier K.E., Crosier P.S. lyve1 expression reveals novel lymphatic vessels and new mechanisms for lymphatic vessel development in zebrafish. Development 2012, 139:2381-2391.
8. Yang Y., Garcia-Verdugo J.M., Soriano-Navarro M., Srinivasan R.S., Scallan J.P., Singh M.K., Epstein J.A., Oliver G. Lymphatic endothelial progenitors bud from the cardinal vein and intersomitic vessels in mammalian embryos. Blood 2012, 120:2340-2348.
9. R. Hagerling, C. Pollmann, M. Andreas, C. Schmidt, H. Nurmi, R.H. Adams, K. Alitalo, V. Andresen, S. Schulte-Merker, F. Kiefer, A novel multistep mechanism for initial lymphangiogenesis in mouse embryos based on ultramicroscopy, EMBO J (2013) in press.
10. Johnson N.C., Dillard M.E., Baluk P., McDonald D.M., Harvey N.L., Frase S.L., Oliver G. Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity. Genes Dev. 2008, 22:3282-3291.
11. Francois M., Caprini A., Hosking B., Orsenigo F., Wilhelm D., Browne C., Paavonen K., Karnezis T., Shayan R., Downes M., Davidson T., Tutt D., Cheah K.S., Stacker S.A., Muscat G.E., Achen M.G., Dejana E., Koopman P. Sox18 induces development of the lymphatic vasculature in mice. Nature 2008, 456:643-647.
12. You L.R., Lin F.J., Lee C.T., DeMayo F.J., Tsai M.J., Tsai S.Y. Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. Nature 2005, 435:98-104.
13. Lee S., Kang J., Yoo J., Ganesan S.K., Cook S.C., Aguilar B., Ramu S., Lee J., Hong Y.K. Prox1 physically and functionally interacts with COUP-TFII to specify lymphatic endothelial cell fate. Blood 2009, 113:1856-1859.
14. Srinivasan R.S., Geng X., Yang Y., Wang Y., Mukatira S., Studer M., Porto M.P., Lagutin O., Oliver G. The nuclear hormone receptor Coup-TFII is required for the initiation and early maintenance of Prox1 expression in lymphatic endothelial cells. Genes Dev. 2010, 24:696-707.
15. Yamazaki T., Yoshimatsu Y., Morishita Y., Miyazono K., Watabe T. COUP-TFII regulates the functions of Prox1 in lymphatic endothelial cells through direct interaction. Genes Cells 2009, 14:425-434.
16. Lin F.J., Chen X., Qin J., Hong Y.K., Tsai M.J., Tsai S.Y. Direct transcriptional regulation of neuropilin-2 by COUP-TFII modulates multiple steps in murine lymphatic vessel development. J. Clin. Invest. 2010, 120:1694-1707.
17. Yoshimatsu Y., Yamazaki T., Mihira H., Itoh T., Suehiro J., Yuki K., Harada K., Morikawa M., Iwata C., Minami T., Morishita Y., Kodama T., Miyazono K., Watabe T. Ets family members induce lymphangiogenesis through physical and functional interaction with Prox1. J. Cell Sci. 2011, 124:2753-2762.
18. Wilting J., Aref Y., Huang R., Tomarev S.I., Schweigerer L., Christ B., Valasek P., Papoutsi M. Dual origin of avian lymphatics. Dev. Biol. 2006, 292:165-173.
19. Ny A., Koch M., Schneider M., Neven E., Tong R.T., Maity S., Fischer C., Plaisance S., Lambrechts D., Heligon C., Terclavers S., Ciesiolka M., Kalin R., Man W.Y., Senn I., Wyns S., Lupu F., Brandli A., Vleminckx K., Collen D., Dewerchin M., Conway E.M., Moons L., Jain R.K., Carmeliet P. A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat. Med. 2005, 11:998-1004.
20. Buttler K., Ezaki T., Wilting J. Proliferating mesodermal cells in murine embryos exhibiting macrophage and lymphendothelial characteristics. BMC Dev. Biol. 2008, 8:43.
21. Gordon E.J., Rao S., Pollard J.W., Nutt S.L., Lang R.A., Harvey N.L. Macrophages define dermal lymphatic vessel calibre during development by regulating lymphatic endothelial cell proliferation. Development 2010, 137:3899-3910.
22. Srinivasan R.S., Oliver G. Prox1 dosage controls the number of lymphatic endothelial cell progenitors and the formation of the lymphovenous valves. Genes Dev 2011, 25:2187-2197.
23. Bertozzi C.C., Hess P.R., Kahn M.L. Platelets: covert regulators of lymphatic development. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2368-2371.
24. Karkkainen M.J., Haiko P., Sainio K., Partanen J., Taipale J., Petrova T.V., Jeltsch M., Jackson D.G., Talikka M., Rauvala H., Betsholtz C., Alitalo K. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 2004, 5:74-80.
25. Bos F.L., Caunt M., Peterson-Maduro J., Planas-Paz L., Kowalski J., Karpanen T., van Impel A., Tong R., Ernst J.A., Korving J., van Es J.H., Lammert E., Duckers H.J., Schulte-Merker S. CCBE1 is essential for mammalian lymphatic vascular development and enhances the lymphangiogenic effect of vascular endothelial growth factor-C in vivo. Circ. Res. 2011, 109:486-491.
26. Hogan B.M., Bos F.L., Bussmann J., Witte M., Chi N.C., Duckers H.J., Schulte-Merker S. Ccbe1 is required for embryonic lymphangiogenesis and venous sprouting. Nat. Genet. 2009, 41:396-398.
27. Alders M., Hogan B.M., Gjini E., Salehi F., Al-Gazali L., Hennekam E.A., Holmberg E.E., Mannens M.M., Mulder M.F., Offerhaus G.J., Prescott T.E., Schroor E.J., Verheij J.B., Witte M., Zwijnenburg P.J., Vikkula M., Schulte-Merker S., Hennekam R.C. Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. Nat. Genet. 2009, 41:1272-1274.
28. Ferrell R.E., Levinson K.L., Esman J.H., Kimak M.A., Lawrence E.C., Barmada M.M., Finegold D.N. Hereditary lymphedema: evidence for linkage and genetic heterogeneity. Hum. Mol. Genet. 1998, 7:2073-2078.
29. Veikkola T., Jussila L., Makinen T., Karpanen T., Jeltsch M., Petrova T.V., Kubo H., Thurston G., McDonald D.M., Achen M.G., Stacker S.A., Alitalo K. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 2001, 20:1223-1231.
30. Haiko P., Makinen T., Keskitalo S., Taipale J., Karkkainen M.J., Baldwin M.E., Stacker S.A., Achen M.G., Alitalo K. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol. Cell. Biol. 2008, 28:4843-4850.
31. Zhang L., Zhou F., Han W., Shen B., Luo J., Shibuya M., He Y. VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis. Cell Res. 2010, 20:1319-1331.
32. Nilsson I., Bahram F., Li X., Gualandi L., Koch S., Jarvius M., Soderberg O., Anisimov A., Kholova I., Pytowski B., Baldwin M., Yla-Herttuala S., Alitalo K., Kreuger J., Claesson-Welsh L. VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J. 2010, 29:1377-1388.
33. Wirzenius M., Tammela T., Uutela M., He Y., Odorisio T., Zambruno G., Nagy J.A., Dvorak H.F., Yla-Herttuala S., Shibuya M., Alitalo K. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J. Exp. Med. 2007, 204:1431-1440.
34. Xu Y., Yuan L., Mak J., Pardanaud L., Caunt M., Kasman I., Larrivee B., Del Toro R., Suchting S., Medvinsky A., Silva J., Yang J., Thomas J.L., Koch A.W., Alitalo K., Eichmann A., Bagri A. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J. Cell Biol. 2010, 188:115-130.
35. Yuan L., Moyon D., Pardanaud L., Breant C., Karkkainen M.J., Alitalo K., Eichmann A. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 2002, 129:4797-4806.
36. Makinen T., Adams R.H., Bailey J., Lu Q., Ziemiecki A., Alitalo K., Klein R., Wilkinson G.A. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev. 2005, 19:397-410.
37. Wang Y., Nakayama M., Pitulescu M.E., Schmidt T.S., Bochenek M.L., Sakakibara A., Adams S., Davy A., Deutsch U., Luthi U., Barberis A., Benjamin L.E., Makinen T., Nobes C.D., Adams R.H. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010, 465:483-486.
38. Phng L.K., Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev. Cell 2009, 16:196-208.
39. Zheng W., Tammela T., Yamamoto M., Anisimov A., Holopainen T., Kaijalainen S., Karpanen T., Lehti K., Yla-Herttuala S., Alitalo K. Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor. Blood 2011, 118:1154-1162.
40. Geudens I., Herpers R., Hermans K., Segura I., Ruiz de Almodovar C., Bussmann J., De Smet F., Vandevelde W., Hogan B.M., Siekmann A., Claes F., Moore J.C., Pistocchi A.S., Loges S., Mazzone M., Mariggi G., Bruyere F., Cotelli F., Kerjaschki D., Noel A., Foidart J.M., Gerhardt H., Ny A., Langenberg T., Lawson N.D., Duckers H.J., Schulte-Merker S., Carmeliet P., Dewerchin M. Role of delta-like-4/Notch in the formation and wiring of the lymphatic network in zebrafish. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1695-1702.
41. Niessen K., Zhang G., Ridgway J.B., Chen H., Kolumam G., Siebel C.W., Yan M. The Notch1-Dll4 signaling pathway regulates mouse postnatal lymphatic development. Blood 2011, 118:1989-1997.
42. Shawber C.J., Funahashi Y., Francisco E., Vorontchikhina M., Kitamura Y., Stowell S.A., Borisenko V., Feirt N., Podgrabinska S., Shiraishi K., Chawengsaksophak K., Rossant J., Accili D., Skobe M., Kitajewski J. Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J. Clin. Invest. 2007, 117:3369-3382.
43. Kang J., Yoo J., Lee S., Tang W., Aguilar B., Ramu S., Choi I., Otu H.H., Shin J.W., Dotto G.P., Koh C.J., Detmar M., Hong Y.K. An exquisite cross-control mechanism among endothelial cell fate regulators directs the plasticity and heterogeneity of lymphatic endothelial cells. Blood 2010, 116:140-150.
44. Yao L.C., Baluk P., Srinivasan R.S., Oliver G., McDonald D.M. Plasticity of button-like junctions in the endothelium of airway lymphatics in development and inflammation. Am. J. Pathol. 2012, 180:2561-2575.
45. Sabine A., Agalarov Y., Maby-El Hajjami H., Jaquet M., Hagerling R., Pollmann C., Bebber D., Pfenniger A., Miura N., Dormond O., Calmes J.M., Adams R.H., Makinen T., Kiefer F., Kwak B.R., Petrova T.V. Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation. Dev. Cell 2012, 22:430-445.
46. E. Bazigou, T. Makinen, Flow control in our vessels: vascular valves make sure there is no way back, Cell. Mol. Life Sci. (2012).
47. Petrova T.V., Karpanen T., Norrmen C., Mellor R., Tamakoshi T., Finegold D., Ferrell R., Kerjaschki D., Mortimer P., Yla-Herttuala S., Miura N., Alitalo K. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat. Med. 2004, 10:974-981.
48. Mellor R.H., Brice G., Stanton A.W., French J., Smith A., Jeffery S., Levick J.R., Burnand K.G., Mortimer P.S. Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb. Circulation 2007, 115:1912-1920.
49. Norrmen C., Ivanov K.I., Cheng J., Zangger N., Delorenzi M., Jaquet M., Miura N., Puolakkainen P., Horsley V., Hu J., Augustin H.G., Yla-Herttuala S., Alitalo K., Petrova T.V. FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J. Cell Biol. 2009, 185:439-457.
50. Lutter S., Xie S., Tatin F., Makinen T. Smooth muscle-endothelial cell communication activates Reelin signaling and regulates lymphatic vessel formation. J. Cell Biol. 2012, 197:837-849.
51. Jurisic G., Maby-El Hajjami H., Karaman S., Ochsenbein A.M., Alitalo A., Siddiqui S.S., Ochoa Pereira C., Petrova T.V., Detmar M. An unexpected role of semaphorin3a-neuropilin-1 signaling in lymphatic vessel maturation and valve formation. Circ. Res. 2012, 111:426-436.
52. Bouvree K., Brunet I., Del Toro R., Gordon E., Prahst C., Cristofaro B., Mathivet T., Xu Y., Soueid J., Fortuna V., Miura N., Aigrot M.S., Maden C.H., Ruhrberg C., Thomas J.L., Eichmann A. Semaphorin3A, Neuropilin-1, and PlexinA1 are required for lymphatic valve formation. Circ. Res. 2012, 111:437-445.
53. Pflicke H., Sixt M. Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. J. Exp. Med. 2009, 206:2925-2935.
54. Dellinger M., Hunter R., Bernas M., Gale N., Yancopoulos G., Erickson R., Witte M. Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice. Dev. Biol. 2008, 319:309-320.
55. Danussi C., Spessotto P., Petrucco A., Wassermann B., Sabatelli P., Montesi M., Doliana R., Bressan G.M., Colombatti A. Emilin1 deficiency causes structural and functional defects of lymphatic vasculature. Mol. Cell. Biol. 2008, 28:4026-4039.
56. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., Choi N.C., Mathisen D., Wain J., Mark E.J., Munn L.L., Jain R.K. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.
57. Alitalo A., Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 2012, 31:4499-4508.
58. R. Shayan, R. Inder, T. Karnezis, C. Caesar, K. Paavonen, M.W. Ashton, G.B. Mann, G.I. Taylor, M.G. Achen and S.A. Stacker, Tumor location and nature of lymphatic vessels are key determinants of cancer metastasis, Clin. Exp. Metastasis 2012.
59. Christiansen A., Detmar M. Lymphangiogenesis and cancer. Genes Cancer 2011, 2:1146-1158.
60. Karnezis T., Shayan R., Caesar C., Roufail S., Harris N.C., Ardipradja K., Zhang Y.F., Williams S.P., Farnsworth R.H., Chai M.G., Rupasinghe T.W., Tull D.L., Baldwin M.E., Sloan E.K., Fox S.B., Achen M.G., Stacker S.A. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 2012, 21:181-195.
61. He Y., Rajantie I., Pajusola K., Jeltsch M., Holopainen T., Yla-Herttuala S., Harding T., Jooss K., Takahashi T., Alitalo K. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005, 65:4739-4746.
62. Duong T., Proulx S.T., Luciani P., Leroux J.C., Detmar M., Koopman P., Francois M. Genetic ablation of SOX18 function suppresses tumor lymphangiogenesis and metastasis of melanoma in mice. Cancer Res. 2012, 72:3105-3114.
63. Zumsteg A., Christofori G. Myeloid cells and lymphangiogenesis. Cold Spring Harbor Perspect Med 2012, 2:a006494.
64. He Y., Rajantie I., Ilmonen M., Makinen T., Karkkainen M.J., Haiko P., Salven P., Alitalo K. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res. 2004, 64:3737-3740.
65. Caunt M., Mak J., Liang W.C., Stawicki S., Pan Q., Tong R.K., Kowalski J., Ho C., Reslan H.B., Ross J., Berry L., Kasman I., Zlot C., Cheng Z., Le Couter J., Filvaroff E.H., Plowman G., Peale F., French D., Carano R., Koch A.W., Wu Y., Watts R.J., Tessier-Lavigne M., Bagri A. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008, 13:331-342.
66. He Y., Kozaki K., Karpanen T., Koshikawa K., Yla-Herttuala S., Takahashi T., Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 2002, 94:819-825.
67. Larrieu-Lahargue F., Welm A.L., Bouchecareilh M., Alitalo K., Li D.Y., Bikfalvi A., Auguste P. Blocking Fibroblast Growth Factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis. PLoS One 2012, 7:e39540.
68. Cao R., Ji H., Feng N., Zhang Y., Yang X., Andersson P., Sun Y., Tritsaris K., Hansen A.J., Dissing S., Cao Y. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:15894-15899.
69. Karkkainen M.J., Saaristo A., Jussila L., Karila K.A., Lawrence E.C., Pajusola K., Bueler H., Eichmann A., Kauppinen R., Kettunen M.I., Yla-Herttuala S., Finegold D.N., Ferrell R.E., Alitalo K. A model for gene therapy of human hereditary lymphedema. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:12677-12682.
70. Mellor R.H., Hubert C.E., Stanton A.W., Tate N., Akhras V., Smith A., Burnand K.G., Jeffery S., Makinen T., Levick J.R., Mortimer P.S. Lymphatic dysfunction, not aplasia, underlies Milroy disease. Microcirculation 2010, 17:281-296.
71. Lim K.C., Hosoya T., Brandt W., Ku C.J., Hosoya-Ohmura S., Camper S.A., Yamamoto M., Engel J.D. Conditional Gata2 inactivation results in HSC loss and lymphatic mispatterning. J. Clin. Invest. 2012, 122:3705-3717.
72. Au A.C., Hernandez P.A., Lieber E., Nadroo A.M., Shen Y.M., Kelley K.A., Gelb B.D., Diaz G.A. Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans. Am. J. Hum. Genet. 2010, 87:436-444.